Cargando…
Innovation in Oncology Drug Development
Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells to exhibit uncontrolled growth while circumventing normal mechanisms of apoptosis and their ability to migrate and invade normal tissues while evading recognition and destruction by the immun...
Autores principales: | Huber, Matthew, Huber, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930717/ https://www.ncbi.nlm.nih.gov/pubmed/31911803 http://dx.doi.org/10.1155/2019/9683016 |
Ejemplares similares
-
Key drivers of biomedical innovation in cancer drug discovery
por: Huber, Margit A, et al.
Publicado: (2015) -
Bridging the innovation gap: blueprint for the innovative enterprise
por: Huber, Daniel, et al.
Publicado: (2017) -
Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs
por: Pauwels, Kim, et al.
Publicado: (2016) -
Innovating Strategies and Tailored Approaches in Neuro-Oncology
por: Picca, Alberto, et al.
Publicado: (2022) -
Strategies for modern biomarker and drug development in oncology
por: Smith, Alan D, et al.
Publicado: (2014)